Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium
26 6월 2023 - 9:30PM
Artelo Biosciences,
Inc.
(Nasdaq: ARTL), a
clinical-stage pharmaceutical company focused on modulating
lipid-signaling pathways to develop treatments for people living
with cancer, pain, and neurological conditions, announced that
Professor Saoirse O’Sullivan, Vice President of Translational
Sciences at Artelo, presented important new data from multiple
preclinical studies regarding ART12.11, Artelo’s patented
cannabidiol (CBD) cocrystal, on Sunday, June 25th, at the
33rd International Cannabinoid Research Society (ICRS)
Symposium in Toronto, Ontario, Canada.
"We are delighted to have the opportunity to disclose new, and
potentially groundbreaking research findings from our ongoing,
preclinical development program with ART12.11, which demonstrate
improved bioavailability and efficacy in nonclinical models of
stress-induced anxiety versus CBD,” said Gregory D. Gorgas,
President and Chief Executive Officer of Artelo. “Given the strong
potential safety profile and latest efficacy data, we believe
ART12.11 has an opportunity to play a major role within the global
anxiety and depression market, which Fortune Market Insights
estimates to be in excess of $11 billion. These latest results
provide us further confidence of the potential of ART12.11 to
improve outcomes, especially for people suffering from anxiety
disorders and the complications of PTSD. Looking ahead, our
proprietary CBD cocrystal will be a key element of our overarching
strategy to introduce innovative, patented and differentiated
therapeutic solutions into clinical practice for patients facing
significant unmet needs."
“As a follow up to an initial single dose study with ART12.11, a
multiple dose pharmacokinetic animal study conducted at different
research laboratories, showed that this novel cocrystal form of CBD
demonstrated improved pharmaceutical properties, including
solubility and dissolution, and delivered higher plasma levels of
CBD and its major metabolite compared to CBD alone,” said Professor
Saoirse O’Sullivan. In addition, new data from a behavioral rodent
model of chronic stress conducted at the laboratory of Professor
Steven Laviolette at the University of Western Ontario, Canada,
also presented at the ICRS showed Artelo’s cocrystal had strong
anxiolytic, anti-depressive, and pro-social effects. “In Dr.
Laviolette’s behavioral research, ART12.11 outperformed CBD dosed
at three times the amount of CBD contained in our cocrystal
composition,” added Professor O’Sullivan.
About ART12.11ART12.11 is a proprietary
cocrystal composition of cannabidiol (CBD). It is isolated as a
single crystalline form that offers biopharmaceutic advantages over
compositions of CBD that exhibit solid polymorphism (i.e., the
ability to manifest different forms). Preclinical studies of
ART12.11 have exhibited superior pharmacokinetics compared to other
forms of CBD. With improved pharmaceutical properties, Artelo
believes a more consistent and improved bioavailability profile may
ultimately lead to improved safety and efficacy, thus making
ART12.11 a preferred CBD pharmaceutical composition.
About the International Cannabinoid Research
SocietyThe International Cannabinoid Research
Society (ICRS) is the premier global scientific association
with more than 650 international members from 40 countries, all
active researchers in the field of endogenous, plant-derived, and
synthetic cannabinoids and related bioactive lipids. In addition to
acting as a source for impartial information on cannabis and the
cannabinoids, the main role of the ICRS is to provide an open forum
for researchers to meet and discuss their research. The ICRS
Symposium is being held at the Marriott Downtown at CF Toronto
Eaton Centre, Toronto, Canada, from June 24-29, 2023. Interested
parties may follow @ICRS_Society on Twitter.
About Artelo BiosciencesArtelo Biosciences,
Inc. is a clinical stage pharmaceutical company dedicated to
the development and commercialization of proprietary therapeutics
that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, neuropathy, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking StatementsThis press release
contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and Private Securities Litigation
Reform Act, as amended, including those relating to the Company’s
product development, clinical and regulatory timelines, market
opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth
opportunities and other statement that are predictive in nature.
These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events and involve known and unknown risks,
uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such factors include those set
forth in the Company’s filings with the Securities and Exchange
Commission, including our ability to raise additional capital in
the future. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date of this press release. The Company undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise,
except to the extent required by applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Artelo Biosciences (NASDAQ:ARTL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024